Aclarubicin
- Generic Name
- Aclarubicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H53NO15
- CAS Number
- 57576-44-0
- Unique Ingredient Identifier
- 74KXF8I502
- Indication
对急性白血病、恶性淋巴瘤、胃癌、肺癌、乳腺癌和卵巢癌等有䓬越疗效，对多柔比星、柔红霉素耐药的病例亦有效，并且脱发、口腔炎等均较轻。
- Associated Conditions
- -
- Associated Therapies
- -
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanxi Bethune Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05726110
- Locations
- 🇨🇳
Tao Wang, Taiyuan, Shanxi, China
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 34
- Registration Number
- NCT04254640
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT03181815
- Locations
- 🇨🇳
Liang Wang, Guangzhou, Guangdong, China
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 120
- Registration Number
- NCT03045627
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT02723448
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT01690507
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳Navy General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath